Elevance Health stock
ELVNYSEElevance Health Inc., HealthcareISIN US0367521038
69Score 69 out of 100, Neutral
Price and trend
77 / 100
Price history
+36% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 3.5% below its 52-week high. Largest decline in 20 years: 67% (December 2007 to November 2008).
Chart figures for advanced users
- SMA 50$414.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$374.65
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$280.74
- The lowest closing price of the last twelve months.
- Resistance$445.28
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Elevance Health Inc. belongs to the Medical (Healthcare Plans) industry (United States) and, with a market value of $92.79B, is number 3 of 12 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $199.13B (up 12.6% year on year) and earnings of $5.66B (down 5.3%).
- For fiscal 2026, analysts expect on average revenue of $200.07B (up 0.5%) and adjusted earnings per share of $29.05 (down 3.7%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 157 of 714 in Healthcare, median 53.
- The P/E is 18.2 (Medical (Healthcare Plans) median 23, own median of recent years 16.8).
- Our model puts fair value at $572.48, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 15 years.Capital allocation 79
- Share buybacksShare count down 12% since 2020.Capital allocation 79
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 90
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and capital allocation, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $440.37 and expensive above $817.83 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $601.54 (cash-flow model) and $543.42 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $521.05, at 7.8% it would be $649.73.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (23).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3.6% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 26%, operating 4%, net 3%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 27 Jan 2027in 76 days
- Last reported
- 21 Oct 2026EPS reported $6.99 (expected $4.71)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 6.6% since 15 Oct 2026.
- Earnings per share
- $29.05+6.6%
- Revenue
- $200.07B+1.5%
- Earnings per share
- $30.25+2.1%
- Revenue
- $205.03B+1.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −12.6%2026 adjusted EPS guidance raised to at least $27 and operating cash flow to at least $6 billion.
“Our second quarter operating results support raising our full-year 2026 adjusted diluted earnings per share guidance to at least $27 while preserving appropriate prudence in our outlook.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 15 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $1.37M in total. 4 insiders sold, $6.06M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Lavu RatnakarSale
5 Nov 2026, EVP & Chief Digital Info Ofr
- Shares
- 1,300
- Price
- $440.00
- Value
- $572,000
- Kaye MarkSale
22 Oct 2026, EVP & CFO
- Shares
- 10,584
- Price
- $440.13
- Value
- $4.66M
- Peru Ramiro GPurchase
17 Jul 2026, Board
- Shares
- 1,000
- Price
- $366.05
- Value
- $366,050
Show 4 more
- Boudreaux GailPurchase
17 Jul 2026, President and CEO
- Shares
- 2,725
- Price
- $367.79
- Value
- $1M
- Penczek Ronald WSale
12 Jun 2026, CAO & Controller
- Shares
- 369
- Price
- $403.16
- Value
- $148,766
- Dixon Robert L JRSale
11 Jun 2026, Board
- Shares
- 151
- Price
- $401.77
- Value
- $60,667
- Penczek Ronald WSale
19 May 2026, CAO & Controller
- Shares
- 1,531
- Price
- $403.13
- Value
- $617,192
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Elevance Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Plans)
The next larger and next smaller companies by market value
- UnitedHealth GroupUNH $361.04B67
- CVS HealthCVS $114.54B60
- CignaCI $79.43B66
- HumanaHUM $53.6B63
- CenteneCNC $34.89B54
- Molina HealthcareMOH $10.92B50
- Oscar HealthOSCR $9.93B71
- BradsaudeSAUD3.SA $8.69B80
ETFs that hold Elevance Health
Held by 66 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.42% | 0.18% | €837.43M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.37% | 0.15% | €3.27B |
| iShares MSCI World Value Factor Advanced UCITS ETFCBUI | 0.96% | 0.25% | €1.53B |
Show 5 more
| iShares Edge MSCI USA Value Factor UCITS ETFQDVI | 0.76% | 0.20% | €2.9B |
| iShares MSCI USA SRI UCITS ETFQDVR | 0.68% | 0.20% | €2.98B |
| iShares Edge MSCI World Minimum Volatility UCITS ETF USDIQQ0 | 0.49% | 0.30% | €2.61B |
| iShares Ageing Population UCITS ETF2B77 | 0.49% | 0.40% | €807M |
| iShares Edge MSCI USA Minimum Volatility Advanced UCITS ETFMVEA | 0.48% | 0.20% | €117.82M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.